Diplomat Mulls Strategic Options, Settles Class-Action Lawsuit
September 1, 2019
Longtime industry presence Diplomat Pharmacy, Inc. recently said it was “reviewing strategic alternatives” as the company continues to post losses. Its specialty infusion unit is doing well in a competitive industry, while its PBM unit’s struggles persist. The announcement also came a little more than a week before the company settled a class-action lawsuit for $14.1 million. It’s anyone’s guess as to what the ultimate outcome will be for the company, which went public in 2014 after almost 40 years of independence (RSP 7/14, p. 1).